Board of Directors Recommends a Vote FOR Each Proposal, Including a Reverse Stock Split Authorization Intended to Provide Flexibility to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement Stockholders
CEO Jonathan Cohen to Discuss Laboratory Franchise Model, 2027 Licensing Plans, Potential Acquisitions, FDA Strategy, and Firefighter Cancer Screening Initiatives Webinar to Be Held Wednesday, November 4, 2026 at 12:00
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) (the "Company"), an
President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar
CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader
CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader
Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5%
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration
Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and
Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc.
Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access to Management
Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc.
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs"
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent
